“The existing scenario has exposed some structural weaknesses from the EU’s medicines provide chain in addition to a high dependence on non-EU countries for active pharmaceutical ingredients,” Kyriakides stated. She proposed that provide chain issues be addressed in an EU pharmaceutical method expec